Who are Tauroursodeoxycholic Acid Capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tauroursodeoxycholic Acid, BDD with UDCA, Doxycycline and tauroursodeoxycholic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tauroursodeoxycholic-acid-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tauroursodeoxycholic Acid Capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tauroursodeoxycholic Acid Capsules (Tauroursodeoxycholic Acid Capsules) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid derivative. Area: Neurology.

phase 3 Bile acid derivative IRE1α, PERK Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Tauroursodeoxycholic Acid Capsules (Tauroursodeoxycholic Acid Capsules) — Beijing Friendship Hospital. Tauroursodeoxycholic acid is a bile acid derivative that modulates the unfolded protein response (UPR) and reduces endoplasmic reticulum stress.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tauroursodeoxycholic Acid Capsules TARGET	Tauroursodeoxycholic Acid Capsules	Beijing Friendship Hospital	phase 3	Bile acid derivative	IRE1α, PERK
Tauroursodeoxycholic Acid	Tauroursodeoxycholic Acid	Johns Hopkins University	marketed	Bile acid derivative / Chemical chaperone	Endoplasmic reticulum stress pathways; TGR5 receptor (partial)
BDD with UDCA	BDD with UDCA	Ewha Womans University Mokdong Hospital	phase 3	Bile acid derivative combination	FXR (farnesoid X receptor) / TGR5 (likely)
Doxycycline and tauroursodeoxycholic acid	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid derivative class)

Beijing Friendship Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tauroursodeoxycholic Acid Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/tauroursodeoxycholic-acid-capsules. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing